Precigen Inc
Precigen Inc (PGEN) is a clinical-stage biotechnology company focused on developing genetic medicines, cell and gene therapies and biologics. The business pursues a range of platform approaches designed to modify or harness the immune system and cellular machinery, with several preclinical and clinical programmes in its pipeline. With a market capitalisation of about $1.44 billion, Precigen is relatively small compared with large pharmaceutical companies and may be more sensitive to clinical, regulatory and financing events. Investors often watch trial readouts, regulatory milestones and partnership activity as potential catalysts. Biotech investing carries distinct risks: clinical outcomes can be binary, development timelines are long and additional capital may be required. This summary provides general, educational information and is not personalised investment advice. Consider whether the stock fits your risk tolerance and investment horizon, and consult a financial adviser for tailored guidance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Precigen Inc's stock with a target price of $8.5, indicating good growth potential.
Financial Health
Precigen Inc is generating modest revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PGEN
Pioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can move the share price; these events are worth watching, though outcomes are uncertain.
Platform Potential
The company’s gene and cell therapy platforms offer broad scientific reach, but technical hurdles and competition mean results are not guaranteed.
Partnerships Matter
Collaborations and licensing deals can de‑risk programmes or provide funding, yet terms and timings vary and may not remove development risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
